Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Cancer|February 1, 1993
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerA Yagoda, D PetrylakThe Urologic Clinics of North America|May 1, 1993
Cytotoxic chemotherapy for advanced renal cell carcinomaA Yagoda, D Petrylak, S ThompsonSeminars in Oncology|December 22, 1999
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916M Hussain, D Petrylak, E Fisher, et al.International Journal of Oncology|May 11, 2011
Preclinical studies of gossypol in prostate carcinomaH Naik, D Petrylak, A Yagoda, et al.The Journal of Urology|March 1, 1992
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancerA D Seidman, H I Scher, D Petrylak, et al.Urologic Oncology|February 13, 2001
Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapyR J. Nejat, R Purohit, E T. Goluboff, et al.Journal of the National Cancer Institute|August 19, 1992
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancerC Cordon-Cardo, D Wartinger, D Petrylak, et al.Investigational New Drugs|June 17, 2000
A phase II pilot study of KW-2189 in patients with advanced renal cell carcinomaE J Small, R Figlin, D Petrylak, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1995
Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activityZ Khaled, D Rideout, K R O'Driscoll, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasmsH I Scher, A Sarkis, V Reuter, et al.Pageof 2